The agreement between GE HealthCare and Salud Digna also includes the deployment of a digital dose management solution to track and manage radiation and contrast exposure within the patient workflow. Per GE HealthCare, the solutions and technologies are aimed at helping improve care for the 20 million patients Salud Digna treats every year. The protocol standardization solution that will be deployed at Salud Digna will likely allow the health system to track and update protocols on CT and MR equipment acros ...

FinkAvenue Earlier this year, I decided to revisit one of the companies that was spun off from the former conglomerate known as General Electric. That happens to be the healthcare side of the firm, known today as GE HealthCare Technologies (NASDAQ:GEHC). From the time I had rated it a 'strong buy' in December of last year through the time that my article was published in March, shares had seen an upside of 35.7%. And since I first rated it a 'strong buy' in early January of 2023, shares had soared by 55.4%. ...

Despite being unwanted and unloved, spinoff stocks are often excellent stocks to buy and hold. Since investors bought shares in the parent company, they are often not interested in the business. This is especially true when they receive shares of the spinoff. They sell the stock, depressing shares. Other times the parent company will weigh down a spinoff with debt. It makes its balance sheet look better while the newly independent company struggles to pay off its loans. Before BorgWarner (NYSE:BWA) spun off ...

GE HealthCare Technologies (GEHC) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this medical technology company have returned -3% over the past month versus the Zacks S&P 500 composite's +7.1% change. The Zacks Medical Info Systems industry, to which GE HealthCare belongs, has lost 4.6% over this period. Now the key question is: Where could the stock b ...

GE HealthCare Technologies (GEHC) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this medical technology company have returned -6.2% over the past month versus the Zacks S&P 500 composite's +0.2% change. The Zacks Medical Info Systems industry, to which GE HealthCare belongs, has lost 10.2% over this period. Now the key question is: Where could the stock be headed in ...

GE Healthcare (GEHC) recently announced the introduction of its head-only MR scanner, SIGNA MAGNUS, which is designed to revolutionize neuroscience research. The system addresses the limitations of whole-body MR scanners, promising to propel advancements in neurology, oncology and psychiatry.This high-performance head-only MR scanner is designed to overcome the limitations of conventional whole-body MR systems, particularly in the realm of neuroscience. With its innovative design and advanced technology, SI ...

Key TakeawaysThe S&P 500 dropped 1.6% on Tuesday, April 30, 2024, cementing its first monthly loss of the year as data on wage growth reignited inflation concerns.GE HealthCare Technologies fell short of quarterly sales and profit estimates, and sales of the medical device maker tumbled.Leidos shares took off after the aviation and defense technology firm topped first-quarter estimates and boosted its guidance. Major U.S. equities indexes tumbled after a report from the Bureau of Labor Statistics showed a h ...

On balance, this stock seems no great bargain.GE HealthCare Technologies (GEHC -13.37%), one-third of the industrial behemoth that used to be General Electric, saw its shares crater 13.7% through 1:30 p.m. ET after reporting a narrow earnings miss Tuesday.Heading into earnings, analysts forecast GE HealthCare would earn $0.91 per share (adjusted for one-time items) on $4.8 billion in the first quarter of 2024 sales. Instead, the company reported a $0.90 per-share profit and sales of $4.6 billion. GE HealthC ...

GE HealthCare (GEHC) reported first-quarter 2024 adjusted earnings per share (EPS) of 90 cents, which aligned with the Zacks Consensus Estimate. However, the bottom line improved 5.9% year over year.GAAP EPS in the quarter was 81 cents, up 97.6% from the year-ago quarter’s level.Revenue DetailsThis Zacks Rank #3 (Hold) company reported revenues of $4.7 billion, down 1.3%, on a reported basis from the prior-year quarter’s recorded number and flat, organically. The decrease in sale volumes was partially offse ...

Financial Performance - For Q1 2024, revenues were $4.6 billion, approximately flat organically year-over-year, following strong double-digit growth in Q1 2023 [5][38] - Adjusted EBIT margin was 14.7%, up 50 basis points year-over-year, with adjusted EPS at $0.90, a 6% increase year-over-year [11][12] - Free cash flow generated was $274 million, reflecting improved working capital [18] Business Segment Performance - Imaging segment had flat organic revenue growth, with EBIT margin up 210 basis points year-over-year [14] - Ultrasound segment saw a 4% decline in organic revenue year-over-year, with EBIT margin decreasing by 200 basis points [15] - Patient Care Solutions experienced a 4% decline in organic revenue year-over-year, with EBIT margin down 310 basis points [16] - Pharmaceutical Diagnostics achieved 8% year-over-year organic growth, driven by price and volume increases [43] Market Performance - EMEA sales were slightly up, while sales in the U.S. and the rest of the world were flat compared to the prior year [12] - China revenue declined low double digits due to prior year stimulus effects and anticorruption impacts [38] Company Strategy and Industry Competition - The company is focused on margin expansion and innovation, with a healthy backlog of $18.7 billion [11][19] - Strategic partnerships, such as the 10-year alliance with OSF HealthCare, are aimed at enhancing care delivery and patient outcomes [35] - The company is investing in advanced manufacturing technologies, including 3D printing, to enhance product capabilities and quality [39] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the growth potential for the remainder of 2024, citing a positive order funnel and expected improvements in the U.S. market [28][36] - The company anticipates a modest sequential improvement in second quarter organic sales growth and adjusted EBIT margin [45] - Management noted that the stimulus in China could provide a positive catalyst for growth, depending on clarity and timing [74][122] Other Important Information - The company plans to host an Investor Day on November 21 in New York City to provide more insights on technology and innovation [26] - The company is actively working on reducing transitional service agreements (TSAs) to optimize its cost structure [40] Q&A Session Summary Question: U.S. year-over-year performance and future outlook - Management acknowledged the flat performance in the U.S. but noted a positive backdrop for order growth and potential improvements in the second half of the year [28][30] Question: Confidence in full year 2024 outlook - Management expressed strong confidence in achieving guidance, citing improved order visibility and easing comparisons as the year progresses [64][66] Question: Order growth translation into revenue growth - Management indicated that a positive book-to-bill ratio and a robust backlog support expectations for mid-single-digit revenue growth [70][85] Question: Impact of stimulus on order submissions - Management noted that clarity on stimulus rules is expected to encourage order submissions, potentially benefiting revenue in the second half of the year [59][74] Question: Updates on FDA approval for Flurpiridaz - Management indicated that Flurpiridaz is expected to be a significant product for cardiac imaging, with updates pending from the FDA [60][61] Question: Pricing environment and its impact - Management confirmed a solid pricing environment, expecting a 1% to 2% pricing impact on sales, which is trending in line with expectations [66][73] Question: Hospital CapEx sentiment and interest rates - Management reported that hospitals are generally in a better financial position, with interest rates not significantly impacting capital spending discussions [92][94]